PRESIDENT & CEO
Dr. Sasi Suda – MD, PhD (USyd)
Dr Suda is a qualified medical practitioner in Australia and has extensive experience in both the pharmaceutical industry and clinical research as a researcher and clinical trial professional.
One of her key drivers is the ability to influence or directly save lives and at Greenlight Clinical she is able to support saving thousands of lives with every new discovery.
The past fifteen years has seen Dr Suda working across a multitude of highly regarded roles as a senior clinical research specialist covering diverse areas including but not limited to regulatory affairs, protocol development and compliance, site management, clinical operations, drug safety and pharmacovigilance.
Dr Suda has held key executive and clinical management roles at Alcon Laboratories, Novo Nordisk Pharmaceuticals and Avexa Australia which has contributed to a wealth of hands on experience in management of complex trials and programs through all stages.
This unique combination of clinical experience and research training has been applied across multiple positions in the pharmaceutical, biotechnology and medical industries in Australia.
Dr Suda is known for her tenacity and passion in this field, she plays a role in every trial that commences within the business and forms positive working relationships with all of our clients. Her dedication to every client and patient is one of the key things that makes working with Greenlight Clinical different.
Clinical Associate Professor
Andrew Chang – MBBS(Hons), PhD (USyd), FRANZCO, FRACS
Associate Professor Andrew Chang is a vitreoretinal surgeon and ophthalmologist. Dr Chang holds an academic appointment of Clinical Associate Professor at the University of Sydney.
Dr Chang is Consultant Vitreoretinal Surgeon and the Head of the Retinal Unit at the Sydney Eye Hospital. He is the Medical Director of Sydney Retina Clinic.
He graduated from University of Sydney Medical School, underwent ophthalmology training at the Sydney Eye Hospital and fellowship training at Royal Victorian Eye and Ear Hospital and in the United States. He was awarded a PhD for research into retinal and choroidal angiography performed in the Universities of California and Sydney.
Dr Chang commitment to international ophthalmology includes Secretary General of the Asia-Pacific Vitreoretinal Society (APVRS). He is a clinician advisor to the Department of Health Australia. He is a Director of the RANZCO Board and the Sydney Eye Hospital Foundation Board. Professional awards include the Achievement Award and Distinguished Service Award of the Asia Pacific Academy of Ophthalmology (APAO) and the RANZCO Excellence in Teaching Award.
Dr Chang is enthusiastically involved in basic science and clinical trials research receiving research grant funding in Australia and USA. His research is extensively published in peer-reviewed scientific literature. He serves on the editorial boards of scientific peer-reviewed journals including Clinical and Experimental Ophthalmology.
In wider healthcare activities, Dr Chang is engaged in the complexities of modern hospital healthcare delivery. He supports new medical drug and devices by engaging in clinical trials development. He is driving strategies aimed at better patient engagement with healthcare professionals using the latest in cloud, IoT and Artificial Intelligence.